Expanded ALS drug coverage to support British Columbians
Posted August 14, 2020 3:33 pm.
This article is more than 5 years old.
VICTORIA (NEWS 1130) — The provincial government has reached a deal with a pharmaceutical company to make a key medication available for those with Lou Gehrig’s disease.
The Ministry of Health will provide coverage of edaravone, or Radicava, as of next Wednesday.
About 480 people in B.C. have been diagnosed with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease where patients typically become unable to move, speak, swallow and breathe as the condition progresses.
In one clinical trial, edaravone helped slow the worsening of this disease in a select ALS patient subpopulation, according to the province.
Edaravone has been under pan-Canadian Pharmaceutical Alliance negotiation since September 2019. The negotiations between the manufacturer, Mitsubishi Tanabe Pharma Corporation, and the pCPA meet B.C.’s cost-related mandate.
“The offer from Mitsubishi Tanabe Pharma Corporation meets British Columbia’s criteria, which is great news for patients suffering from this deadly disease,” Health Minister Adrian Dix says in a release.
“B.C. will continue to support ALS patients through its expansion of coverage of life-changing drugs and research funding to improve the lives of British Columbians.”
It is expected that between 66 to 183 patients will benefit from the coverage in the first year. The list price of edaravone is around $120,000 a year for each patient.
To further support patients living with ALS throughout the province, the ALS Society of British Columbia has raised $1 million and the B.C. government has provided $1 million to match that effort.
“The work of the ALS Society of BC helps provide care to patients, supports clinical trials and research,” Dix says. “This organization has done extraordinary things to enable patients to participate in their care, prolong survival, and improve well-being, and we are happy to support them in that great work.”
The combined $2 million will be used over the next five years to develop an ALS centre of excellence in Vancouver that will not only serve patients in the Vancouver area, but also provincewide through mobile clinics.
